Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NYSEAMERICAN:APHB OTCMKTS:EMBI NYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.02+1.3%$3.11$2.07▼$4.20$95.99M0.5853,834 shs168,839 shsAPHBAmpliphi Biosciences$2.95+4.6%$2.47$0.15▼$1.37$98.69MN/A842,200 shs4,725 shsEMBIEmerald Bioscience$0.00$0.02▼$0.20$24.13M0.4314.24 million shs6.96 million shsZOMZomedica$0.12$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+1.34%+1.00%+2.72%-16.11%-2.89%APHBAmpliphi Biosciences+4.56%+15.64%+22.37%+45.26%+26.55%EMBIEmerald Bioscience0.00%0.00%0.00%0.00%0.00%ZOMZomedica0.00%0.00%0.00%0.00%-23.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.02+1.3%$3.11$2.07▼$4.20$95.99M0.5853,834 shs168,839 shsAPHBAmpliphi Biosciences$2.95+4.6%$2.47$0.15▼$1.37$98.69MN/A842,200 shs4,725 shsEMBIEmerald Bioscience$0.00$0.02▼$0.20$24.13M0.4314.24 million shs6.96 million shsZOMZomedica$0.12$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+1.34%+1.00%+2.72%-16.11%-2.89%APHBAmpliphi Biosciences+4.56%+15.64%+22.37%+45.26%+26.55%EMBIEmerald Bioscience0.00%0.00%0.00%0.00%0.00%ZOMZomedica0.00%0.00%0.00%0.00%-23.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.00Buy$9.00198.01% UpsideAPHBAmpliphi Biosciences 0.00N/AN/AN/AEMBIEmerald Bioscience 0.00N/AN/AN/AZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest EMBI, ANIX, APHB, and ZOM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K463.21N/AN/A$0.59 per share5.12APHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AEMBIEmerald BioscienceN/AN/AN/A1.20N/AN/AZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/12/2025 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AEMBIEmerald Bioscience$1.05M-$0.08N/AN/AN/AN/AN/A-347.62%N/AZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest EMBI, ANIX, APHB, and ZOM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/12/2025Q3 2025ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AEMBIEmerald BioscienceN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89APHBAmpliphi BiosciencesN/AN/AN/AEMBIEmerald Bioscience0.433.593.59ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%APHBAmpliphi BiosciencesN/AEMBIEmerald Bioscience5.58%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%APHBAmpliphi BiosciencesN/AEMBIEmerald Bioscience1.60%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableEMBIEmerald Bioscience4268.07 millionN/ANot OptionableZOMZomedica50979.95 million938.89 millionNot OptionableEMBI, ANIX, APHB, and ZOM HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica and UXR Announce Expanded Distribution Agreement in CanadaSeptember 10 at 6:02 PM | finanznachrichten.deZomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent PracticesAugust 19, 2025 | finanznachrichten.deZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary MedicineAugust 12, 2025 | finanznachrichten.deZomedica Achieves Record Revenue Growth in Q2 2025August 6, 2025 | msn.comNon-Pharmacologic Solutions for Pet Dental Health From Prevention to RecoveryJuly 11, 2025 | dvm360.comDZomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - OcalaJuly 10, 2025 | finanznachrichten.deZomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - MorningstarJune 25, 2025 | morningstar.comMZomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 20, 2025 | finanznachrichten.deTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24, 2025 | click2houston.comCHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comPIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comANYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025EMBI, ANIX, APHB, and ZOM Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.02 +0.04 (+1.34%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$3.04 +0.02 (+0.50%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Ampliphi Biosciences NYSEAMERICAN:APHB$2.95 +0.13 (+4.56%) As of 09/9/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Emerald Bioscience OTCMKTS:EMBIEmerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
